BBOT
BridgeBio Oncology Therapeutics, Inc.
Key Financials
Operating Income
$-145819000
↓ 24852.4%
Net Income
$-134044000
↓ 1863.9%
Total Liabilities
$37.3M
↑ 553.3%
Total Assets
$448.4M
↑ 130.6%
Cash & Equivalents
$373.7M
↑ 1111.3%
EPS (Diluted)
$-4.30
↑ 99.9%
Shareholders' Equity
$411.1M
↑ 11113.6%
Operating Cash Flow
$-113894000.00
↓ 14811.1%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 3/26/2026 | View on SEC |
| 3 | 3/26/2026 | View on SEC |
| 424B3 | 3/26/2026 | View on SEC |
| 8-K | 3/26/2026 | View on SEC |
| 4 | 3/12/2026 | View on SEC |
| 4 | 3/12/2026 | View on SEC |
| 4 | 3/12/2026 | View on SEC |
| 424B3 | 3/6/2026 | View on SEC |
| 10-K | 3/5/2026 | View on SEC |
| 8-K | 3/5/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | BBOT |
| Company Name | BridgeBio Oncology Therapeutics, Inc. |
| CIK | 1869105 |
| Sector | Pharmaceutical Preparations |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 857 702 0377 |